Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc.

SG&A Trends in Biopharma: BioMarin vs. Supernus

__timestampBioMarin Pharmaceutical Inc.Supernus Pharmaceuticals, Inc.
Wednesday, January 1, 201430215600072471000
Thursday, January 1, 201540227100089204000
Friday, January 1, 2016476593000106010000
Sunday, January 1, 2017554336000137905000
Monday, January 1, 2018604353000159888000
Tuesday, January 1, 2019680924000158425000
Wednesday, January 1, 2020737669000200677000
Friday, January 1, 2021759375000304759000
Saturday, January 1, 2022854009000377221000
Sunday, January 1, 2023937300000336361000
Loading chart...

Unleashing insights

A Decade of SG&A Trends in Biopharma

In the ever-evolving landscape of biopharmaceuticals, operational efficiency is paramount. Over the past decade, BioMarin Pharmaceutical Inc. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A costs have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, Supernus Pharmaceuticals has seen a more modest increase of approximately 360%, indicating a more conservative growth strategy.

Key Insights

  • BioMarin: From 2014 to 2023, BioMarin's SG&A expenses grew steadily, peaking in 2023, showcasing its commitment to scaling operations.
  • Supernus: Despite a slower start, Supernus's expenses have shown a significant uptick since 2020, suggesting a strategic pivot towards growth.
    These trends highlight the diverse strategies employed by biopharma companies in managing operational costs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025